KARD News & Events

Kardiga, a clinical-stage precision therapeutics company developing medicines that target cardiovascular diseases, priced its initial public offering of 25M shares of common stock at $16 per share. The deal size was increased to 25M from 23.3M shares and priced at high end of the $14.00-$16.00 range. J.P. Morgan, Jefferies, Leerink Partners, and TD Securities are the underwriters for the offering. The shares trade on the Nasdaq under the ticker symbol "KARD."

The deal size was increased to 25.0M from 23.3M shares and priced at high end of $14.00-$16.00 range. JPMorgan, Jefferies, Leerink and TD Cowen are acting as joint book running managers for the offering.